Agios Pharmaceuticals, Inc. (AGIO) Upgraded to Hold by ValuEngine
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday.
Several other research firms have also commented on AGIO. Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 1st. Cann reissued a “buy” rating and issued a $75.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, April 19th. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 18th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 18th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $61.00 price target on shares of Agios Pharmaceuticals in a research note on Tuesday, April 18th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $62.88.
Agios Pharmaceuticals (NASDAQ:AGIO) traded up 3.07% during midday trading on Thursday, hitting $59.18. 833,983 shares of the stock traded hands. The firm’s market cap is $2.85 billion. Agios Pharmaceuticals has a 12-month low of $35.84 and a 12-month high of $67.74. The company’s 50-day moving average is $49.86 and its 200 day moving average is $48.86.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The business had revenue of $10.51 million during the quarter, compared to analyst estimates of $9.65 million. During the same quarter last year, the firm posted ($0.64) earnings per share. The business’s revenue for the quarter was down 66.4% compared to the same quarter last year. On average, analysts anticipate that Agios Pharmaceuticals will post ($6.44) EPS for the current fiscal year.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the transaction, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Biller sold 4,292 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $55.00, for a total transaction of $236,060.00. The disclosure for this sale can be found here. Insiders sold a total of 26,600 shares of company stock worth $1,423,540 over the last ninety days. Corporate insiders own 10.55% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. C WorldWide Group Holding A S bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $105,000. Bank of Montreal Can raised its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $129,000. Russell Investments Group Ltd. raised its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares during the last quarter. Finally, Advantage Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 1,700 shares during the last quarter. 83.99% of the stock is currently owned by institutional investors.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.